Literature DB >> 28875420

Prognostic Value of Preoperative Serum Carcinoembryonic Antigen and Carbohydrate Antigen 19-9 After Resection of Ampullary Cancer.

Tobias S Schiergens1, Bernhard W Renz1, Simone Reu2, Jens Neumann2, Rami Al-Sayegh1, Hanno Nieß1, Matthias Ilmer1, Stephan Kruger3, Stefan Boeck3, Volker Heinemann3, Jens Werner1, Axel Kleespies4.   

Abstract

BACKGROUND: The purpose of this study is to investigate the prognostic value of pre-resection serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 after resection of ampullary cancer (AC) in consideration of intestinal (IT) and pancreatobiliary (PT) subtypes.
METHODS: Overall survival (OS) analysis of patients undergoing curative resection of ampullary cancer.
RESULTS: Elevated preoperative CEA (P = 0.013) and CA 19-9 levels (P = 0.030) were significant prognostic factors. Subgroup analysis, however, showed both markers having prognostic value only for the IT subgroup. Pre-resection CEA within normal range identified a subgroup of IT patients with an excellent median survival of 145 months. Compared to other AC patients, this low-risk ITCEA- subpopulation was characterized by less frequent advanced pT stages (pT3/pT4, 41 vs. 62%; P = 0.047) and lymph node involvement (pN+, 30 vs. 65%; P = 0.001). OS of this subgroup was significantly better compared to other AC patients (145 vs. 25 months; HR = 3.8; P < 0.001). By multivariate survival analysis, the patient age, the PT subtype, and an elevated pre-resection serum CEA value were identified as independent prognostic variables.
CONCLUSIONS: In AC, the histomorphologic subclassification is highly relevant regarding the prognostic value of preoperative serum CEA and CA 19-9. IT-patients with normal preoperative CEA represent a favorable subgroup with excellent long-term survival.

Entities:  

Keywords:  Ampullary cancer; CA 19-9; CEA; Intestinal; Pancreaticobiliary

Mesh:

Substances:

Year:  2017        PMID: 28875420     DOI: 10.1007/s11605-017-3489-8

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  36 in total

1.  Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer.

Authors:  Woo Seok Kim; Dong Wook Choi; Seoung Ho Choi; Jin Seok Heo; Dong Do You; Hyung Geun Lee
Journal:  J Surg Oncol       Date:  2011-08-31       Impact factor: 3.454

2.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  J Gastrointest Oncol       Date:  2012-06

3.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer.

Authors:  M A Tempero; E Uchida; H Takasaki; D A Burnett; Z Steplewski; P M Pour
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

4.  [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?].

Authors:  C M Mery; A Duarte-Rojo; F Paz-Pineda; E Gómez; G Robles-Díaz
Journal:  Rev Invest Clin       Date:  2001 Nov-Dec       Impact factor: 1.451

Review 5.  Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

Authors:  M J Duffy; C Sturgeon; R Lamerz; C Haglund; V L Holubec; R Klapdor; A Nicolini; O Topolcan; V Heinemann
Journal:  Ann Oncol       Date:  2009-08-18       Impact factor: 32.976

6.  Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival.

Authors:  Sergio Morini; Giuseppe Perrone; Domenico Borzomati; Bruno Vincenzi; Carla Rabitti; Daniela Righi; Federica Castri; Andrea D Manazza; Daniele Santini; Giuseppe Tonini; Roberto Coppola; Andrea Onetti Muda
Journal:  Pancreas       Date:  2013-01       Impact factor: 3.327

7.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Authors:  Daniele Marrelli; Stefano Caruso; Corrado Pedrazzani; Alessandro Neri; Eduardo Fernandes; Mario Marini; Enrico Pinto; Franco Roviello
Journal:  Am J Surg       Date:  2009-04-17       Impact factor: 2.565

8.  Periampullary adenocarcinoma: analysis of 5-year survivors.

Authors:  C J Yeo; T A Sohn; J L Cameron; R H Hruban; K D Lillemoe; H A Pitt
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

9.  Intestinal-type and pancreatobiliary-type adenocarcinomas: how does ampullary carcinoma differ from other periampullary malignancies?

Authors:  Arne Westgaard; Ewa Pomianowska; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Ann Surg Oncol       Date:  2012-09-07       Impact factor: 5.344

10.  Factors predictive of survival in ampullary carcinoma.

Authors:  J R Howe; D S Klimstra; R D Moccia; K C Conlon; M F Brennan
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

View more
  2 in total

1.  Ampullary Large-Cell Neuroendocrine Carcinoma, a Diagnostic Challenge of a Rare Aggressive Neoplasm: A Case Report and Literature Review.

Authors:  Eleni Karlafti; Maria Charalampidou; Georgia Fotiadou; Ioanna Abba Deka; Georgia Raptou; Filippos Kyriakidis; Stavros Panidis; Aristeidis Ioannidis; Adonis A Protopapas; Smaro Netta; Daniel Paramythiotis
Journal:  Diagnostics (Basel)       Date:  2022-07-25

2.  Circulating Cell-Free DNA as a Prognostic Biomarker in Resectable Ampullary Cancer.

Authors:  Bor-Uei Shyr; Bor-Shiuan Shyr; Shih-Chin Chen; Shih-Ching Chang; Yi-Ming Shyr; Shin-E Wang
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.